Literature DB >> 6487612

Functional characterization of human erythrocyte spectrin alpha and beta chains: association with actin and erythrocyte protein 4.1.

C M Cohen, R C Langley.   

Abstract

Human erythrocyte spectrin alpha and beta chains were purified by preparative sodium dodecyl sulfate gel electrophoresis and also by DEAE-cellulose chromatography in the presence of urea. The purified chains behaved as individual monomers on sucrose gradients and did not form homodimers. Recombination of the chains led to the formation of alpha-beta heterodimers with sedimentation characteristics identical with native alpha-beta dimers. The binding of 125I-labeled band 4.1 to alpha and beta chains was measured by sucrose gradient rate zonal sedimentation and by quantitative immunoassay. It was found that both alpha and beta chains associated with 125I-labeled band 4.1 in a nearly identical manner over the range of band 4.1 concentration studied. The association was abolished by heat denaturation of the spectrin chains or by denaturation of band 4.1 with a 40-fold molar excess of N-ethylmaleimide. As expected, purified beta chains but not alpha chains bound to 125I-labeled ankyrin as measured by a quantitative radioimmunoassay. The binding of purified alpha chains, beta chains, and recombinant alpha-beta heterodimers to F-actin was measured in the presence of band 4.1. We found that alpha or beta chains separately exhibited no band 4.1 dependent association with F-actin but that alpha-beta heterodimers formed by recombination of the chains did. We conclude that spectrin binding to F-actin in the presence of band 4.1 requires the participation of both of spectrin's polypeptide chains.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487612     DOI: 10.1021/bi00314a039

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  The carboxyterminal EF domain of erythroid alpha-spectrin is necessary for optimal spectrin-actin binding.

Authors:  Catherine Korsgren; Samuel E Lux
Journal:  Blood       Date:  2010-06-28       Impact factor: 22.113

2.  Analysis of novel sph (spherocytosis) alleles in mice reveals allele-specific loss of band 3 and adducin in alpha-spectrin-deficient red cells.

Authors:  Raymond F Robledo; Amy J Lambert; Connie S Birkenmeier; Marius V Cirlan; Andreea Flavia M Cirlan; Dean R Campagna; Samuel E Lux; Luanne L Peters
Journal:  Blood       Date:  2010-01-07       Impact factor: 22.113

3.  STAT3: a link between CaMKII-βIV-spectrin and maladaptive remodeling?

Authors:  Mohit Hulsurkar; Ann P Quick; Xander Ht Wehrens
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

4.  The murine mutation jaundiced is caused by replacement of an arginine with a stop codon in the mRNA encoding the ninth repeat of beta-spectrin.

Authors:  M L Bloom; T M Kaysser; C S Birkenmeier; J E Barker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

5.  Calmodulin and calcium-dependent protease I coordinately regulate the interaction of fodrin with actin.

Authors:  A S Harris; J S Morrow
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

6.  Ultrastructure of the intact skeleton of the human erythrocyte membrane.

Authors:  B W Shen; R Josephs; T L Steck
Journal:  J Cell Biol       Date:  1986-03       Impact factor: 10.539

7.  Erythrocyte adducin: a calmodulin-regulated actin-bundling protein that stimulates spectrin-actin binding.

Authors:  S M Mische; M S Mooseker; J S Morrow
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

8.  Lymphoma Thy-1 glycoprotein is linked to the cytoskeleton via a 4.1-like protein.

Authors:  L Y Bourguignon; S J Suchard; E L Kalomiris
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

9.  Beta spectrin bestows protein 4.1 sensitivity on spectrin-actin interactions.

Authors:  T R Coleman; A S Harris; S M Mische; M S Mooseker; J S Morrow
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.